CD7 CAR-T for relapsed or resistant T-cell cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 to 75, and agree by signing consent (or a legal guardian signs if needed).
- Have a diagnosis of T-cell lymphoma or T-cell acute lymphoblastic leukemia, specifically in the relapsed/refractory setting.
- Have recent treatment details that fit the trial (for example, no antibody therapy in the 2 weeks before cell therapy).
- Be well enough to do procedures: ECOG health status 0–2, able to undergo peripheral apheresis (cell collection), and expected survival over 3 months.
- Meet key lab and health safety limits (for example, acceptable liver/kidney function, bilirubin/enzymes not too high, platelets not too low, and no severe uncontrolled breathing or heart problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying whether a new kind of cellular therapy, called anti-CD7 CAR-T, can help people with relapsed or refractory T-cell lymphoma/leukemia by targeting a specific protein (CD7) on their cancer cells. The treatment uses your own immune cells that are reprogrammed to find and destroy the malignant cells.
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
This study tests a new type of immune cell therapy for people whose cancer cells have a specific marker called CD7. The treatment uses modified immune cells (CAR T-cells) to find and attack the cancer. It might help if other treatments haven't worked or the cancer has returned.
This early-stage trial tests a special immune cell treatment that targets a marker called CD7 on cancer cells, aiming to attack and destroy the cancer. It's designed for patients with blood cancers that express CD7 and who haven't had prior gene therapy.
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
Hear when a new T Lymphoblastic Leukemia/Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.